We are live on ! Find out more
SCM

Soleus Capital Management Portfolio holdings

AUM $2.47B
1-Year Est. Return 115.63%
This Fund
S&P 500
This Quarter Est. Return
+14.25%
1 Year Est. Return
+115.63%
3 Year Est. Return
+435.52%
5 Year Est. Return
+604.31%
10 Year Est. Return
–
AUM
$966M
AUM Growth
+$269M
Cap. Flow
+$319M
Cap. Flow %
33.08%
Top 10 Hldgs %
49.6%
Holding
104
New
32
Increased
25
Reduced
14
Closed
27

Top Buys

Rank Stock Value
1
SNN icon
Smith & Nephew
SNN
+$27.6M
2
RIGL icon
Rigel Pharmaceuticals
RIGL
+$20.3M
3
SIBN icon
SI-BONE Inc
SIBN
+$18.8M
4
NTRA icon
Natera
NTRA
+$14.1M
5
JSPR icon
Jasper Therapeutics
JSPR
+$13.8M

Top Sells

Rank Stock Value
1
CVRX icon
CVRx
CVRX
+$18.6M
2
VCEL icon
Vericel Corp
VCEL
+$16.9M
3
LLY icon
Eli Lilly
LLY
+$14.3M
4
HCA icon
HCA Healthcare
HCA
+$8.29M
5
KRYS icon
Krystal Biotech
KRYS
+$8.09M

Sector Composition

Rank Sector Weight
1 Healthcare 81.2%
2 Consumer Staples 1.43%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XBI icon
1
CALL
State Street SPDR S&P Biotech ETF
XBI
$10.2B
$159M 16.42%
+2,080,000
New +$173M
FOCL
2
EDAP TMS S.A.
FOCL
$226M
$58.8M 6.09%
5,312,222
+177,792
+3% +$2.01M
ISEE
3
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$51.8M 5.36%
2,127,043
+12,315
+0.6% +$270K
ACLX
4
DELISTED
Arcellx
ACLX
$38.5M 3.98%
1,248,147
+145,700
+13% +$4.42M
CRL icon
5
Charles River Laboratories
CRL
$10.9B
$31.5M 3.26%
156,096
+54,246
+53% +$12.3M
EXAS
6
DELISTED
Exact Sciences
EXAS
$31M 3.21%
456,500
+169,200
+59% +$10.9M
UTHR icon
7
United Therapeutics
UTHR
$26.3B
$30.5M 3.16%
136,235
+7,967
+6% +$1.96M
IRMD icon
8
iRadimed
IRMD
$1.21B
$30.4M 3.15%
773,694
+28,690
+4% +$1.04M
SNN icon
9
Smith & Nephew
SNN
$12.9B
$27.1M 2.8%
+970,200
New +$27.6M
ORGO icon
10
Organogenesis Holdings
ORGO
$308M
$21M 2.17%
9,853,063
+2,490,000
+34% +$6.15M
SIBN icon
11
SI-BONE Inc
SIBN
$737M
$20.9M 2.16%
+1,060,983
New +$18.8M
SRDX
12
DELISTED
Surmodics
SRDX
$20.3M 2.11%
892,678
+117,367
+15% +$3.02M
CVS icon
13
CVS Health
CVS
$137B
$18.1M 1.87%
243,554
+148,800
+157% +$12.5M
CELC icon
14
Celcuity
CELC
$4.03B
$17.3M 1.79%
1,687,933
+477,705
+39% +$5.24M
RIGL icon
15
Rigel Pharmaceuticals
RIGL
$680M
$16.9M 1.75%
+1,280,302
New +$20.3M
AXGN icon
16
Axogen
AXGN
$2.1B
$16.8M 1.74%
1,779,998
+1,024,000
+135% +$9.37M
NTRA icon
17
Natera
NTRA
$37.5B
$16.3M 1.69%
+294,200
New +$14.1M
RETA
18
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$15.9M 1.64%
+174,592
New +$10.2M
SGEN
19
DELISTED
Seagen Inc. Common Stock
SGEN
$14.4M 1.49%
+71,000
New +$11.4M
PCVX icon
20
Vaxcyte
PCVX
$7.89B
$14.3M 1.48%
380,250
-7,700
-2% -$327K
SKIN icon
21
SkinHealth Systems
SKIN
$94.9M
$13.8M 1.43%
1,089,952
-286,416
-21% -$3.31M
JSPR icon
22
Jasper Therapeutics
JSPR
$22.9M
$13.5M 1.4%
+745,498
New +$13.8M
EPIX
23
DELISTED
ESSA Pharma
EPIX
$12.3M 1.27%
4,145,117
+275,725
+7% +$810K
BCAB icon
24
BioAtla
BCAB
$5.59M
$11.6M 1.2%
86,424
+2,016
+2% +$363K
HUM icon
25
Humana
HUM
$46.7B
$11.5M 1.19%
23,750
-3,000
-11% -$1.48M
1
2 3 4 5

Similar funds

TW
Trajan Wealth Scottsdale, Arizona $2.48B AUM 17.44% 1-Year Est. Return
JC
JB Capital Wethersfield, Connecticut $2.48B AUM 22.31% 1-Year Est. Return
M
Mirova Paris, France $2.46B AUM 11.42% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $2.48B AUM 72.25% 1-Year Est. Return
BW
BIP Wealth Atlanta, Georgia $2.46B AUM 14.38% 1-Year Est. Return
BL
Balentine LLC Atlanta, Georgia $2.48B AUM 17.44% 1-Year Est. Return
FFA
First Foundation Advisors Irvine, California $2.48B AUM 18.56% 1-Year Est. Return
GWM
Greenwich Wealth Management Greenwich, Connecticut $2.45B AUM 39.53% 1-Year Est. Return

Soleus Capital Management's Q1 2023 Portfolio in Review

As of Q1 2023, Soleus Capital Management held 104 positions worth $966M, up 39% from $697M the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Soleus Capital Management deployed $319M of net new capital in Q1 2023, opening 32 new positions and adding to 25 existing holdings. Its largest new stake was Smith & Nephew: 970,200 shares worth $27.1M.

By sector, the portfolio is most concentrated in Healthcare at 81% of assets, down from 97% a quarter earlier, followed by Consumer Staples.

On the sell side, the largest reduction was Vericel Corp, an estimated $16.9M trimmed.

  • Soleus Capital Management's largest Q1 2023 buy was Smith & Nephew: 970,200 shares worth $27.1M.
  • Soleus Capital Management added most to CVS Health in Q1 2023, an estimated $12.5M increase.
  • Soleus Capital Management's biggest Q1 2023 reduction was Vericel Corp, cutting an estimated $16.9M.
  • Soleus Capital Management fully exited CVRx in Q1 2023, selling an estimated $18.6M.
  • Soleus Capital Management's ten largest holdings make up 50% of its $966M portfolio in Q1 2023.
  • Soleus Capital Management opened 32 new positions and closed 27 in Q1 2023.
  • Soleus Capital Management's portfolio value rose 39% quarter-over-quarter to $966M.

Based on Soleus Capital Management's 13F filing for Q1 2023, filed 15 May 2023.